Biotechnology

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

Biotech firm ProJenX reports its novel ALS drug, prosetin, is safe and hits key targets in early trials, offering a new beacon of hope for the disease.

Acurx Pharma's new drug, ibezapolstat, offers a novel weapon against deadly infections like C. diff by sparing good bacteria. Is this the breakthrough we need?

A new partnership between Matica Bio and Cirsium Biosciences aims to shatter the high-cost, closed-off world of gene therapy manufacturing. Is this the key?

As Latus Bio advances its Huntington's therapy to clinic, new CBO Bethany Mancilla brings a history of high-value deals to fuel the company's growth.

The company behind the first FDA-cleared birth control app is expanding into a holistic wellness platform, a strategic move that could redefine the FemTech market.

Renowned cancer researcher Dr. Morag Park takes the helm at the Gairdner Foundation, a key predictor of Nobel Prizes. What does this strategic move mean for global science?

Edgewise Therapeutics unveils strong Phase 2 data for its HCM drug, EDG-7500, showing efficacy without the cardiac risks plaguing market leaders.

A simple blood test for lung cancer completes key validation, signaling potential disruption for the diagnostics market and major savings for healthcare systems.

Bruce Eaton's appointment as Chairman at Broken String isn't just a new hire; it's a strategic move to make its INDUCE-seq technology the industry's gold standard.

A short-seller report alleges ADMA faked 20% growth, triggering a 40% stock collapse and a securities fraud lawsuit with an August 10 investor deadline.

With a major debt financing, French biotech Inventiva is funded through a pivotal Phase 3 trial for its MASH drug, highlighting a strategic shift in biotech funding.

A 125-year-old pest control giant is funding a new generation of scientists, betting that the secrets of insects can solve our biggest future challenges.

Faculty's new AI developer studio promises to cut drug trial planning from weeks to minutes, a major growth signal in the high-stakes life sciences race.

Preliminary data from a randomized trial suggests a personalized medicine approach can reverse cognitive decline, offering a glimmer of hope beyond slowing the disease.

Activist investor Murchinson slams Nano Dimension’s pivot from 3D printing to epigenetics as a 'deeply flawed' deal, citing a 15% stock drop and echoes of past failures.

NeoGenomics is raising $275M via convertible notes. We dissect the sophisticated financing, from dilution-hedging calls to the market impact for investors.

A Chinese firm is expanding its role in the hidden, high-stakes supply chain for semiconductors and advanced manufacturing. Here’s why it matters.

Adaptive Biotechnologies plans to separate its profitable diagnostics arm from its high-potential discovery engine. A deep dive into the financial calculus.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.